Australia | Lessons from recent interlocutory injunctions in pharmaceutical patent cases 
Is it becoming easier to obtain interlocutory injunctions in Australian pharmaceutical patent cases? We provide an overview of recent decisions in Australia’s Federal Court that shine a light on some key lessons for patent owners. Overview In...
Is it becoming easier to obtain interlocutory injunctions in Australian pharmaceutical patent cases? We provide an overview of recent decisions in Australia’s Federal Court that...
Read More
No pay day for Commonwealth in Sanofi pharmaceutical damages claim
BackgroundIn the keenly awaited judgment in Commonwealth of Australia v Sanofi (formerly Sanofi-Aventis)  FCAFC 97, the Full Court of the Federal Court of Australia has upheld the trial judge’s decision that...
BackgroundIn the keenly awaited judgment in Commonwealth of Australia v Sanofi (formerly Sanofi-Aventis)  FCAFC 97, the Full Court of the Federal...
Read More
Sanofi v Eremad Pty Ltd [2013] ATMO 94
This matter concerned an opposition to registration of the mark CLOVIX 75 in respect of class 5 Pharmaceutical preparations being products containing clopidogrel. The mark was opposed by French...
This matter concerned an opposition to registration of the mark CLOVIX 75 in respect of class 5 Pharmaceutical preparations...
Read More